Company: BLTE
Filing Date: 2025-03-17
Form Type: 20-F
Source: 0001410578-25-000356
Chunk: 9

Company: BELITE BIO, INC
Filing Date: 2025-03-17
Form: 20-F
Item: Item 16J
Chunk 9
---
ITEM 16J.    Inside Trading Policy
Our Board of Directors has adopted an Insider Trading Policy setting out policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, senior management, employees and consultants that are reasonably designed to promote compliance with applicable insider trading laws, rules, and regulations, and any listing standards applicable to us.
Our Board of Directors has also adopted a Compensation Recoupment Policy required by the Nasdaq Listing Rule 5608.
Under our Insider Trading Policy, any of our directors, senior management, employees or consultants in possession of material non-public information is prohibited from trading in the securities of our Company as well as from disclosing to a third party such material non-public information (tipping). The Insider Trading Policy also contains restrictions on all directors, executive officers, employees or consultants from trading in the Company’s securities during certain periods of the year (“Black-Out Periods”). Regularly-scheduled Black-Out Periods usually begins on the day immediately following the end of a fiscal quarter and ends on the second trading day following the date of disclosure of the financial results for that quarter. Notwithstanding the foregoing, the Black-Out Periods should not prevent our Company from (i) granting stock options and other equity awards to its personnel as approved by the Board in accordance with applicable laws and regulations; and (ii) automatic purchases or dispositions in accordance with applicable laws and regulations pursuant to any written automatic trading plan established by our Company or any its directors, officers, employees or consultants prior to the relevant periods.
Other than the Rule 10b5-1 Trading Plans adopted by (i) Yu-Hsin Lin, our Chief Executive Officer and Hao-Yuan Chuang, our Chief Financial Officer, on September 27, 2024; (ii) Nathan L. Mata, our Chief Scientific Officer, on December 18, 2024; and (iii) Wan-Shan Chen, our director, on December 13, 2024, we do not have any outstanding share repurchase or automatic trading plan in place.